Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

Crohn's Disease Clinical Trial

— ENTERPRISE  

Official title:

A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02630966
• Other study ID #: Vedolizumab-4003
• Secondary ID: 2015-000852-12U1
• Status: Completed
• Phase: Phase 4
• Start date: August 10, 2016
• Est. completion date: November 14, 2018

Study information

• Verified date: November 2019
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).

Description:

The drug being tested in this study is called vedolizumab IV. Vedolizumab IV is being tested to treat people who have fistulizing CD. This study will look at fistula healing in people who take vedolizumab IV.

The study is planned to enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

• Group 1: Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 14 and 22, and a placebo infusion at Week 10 (dummy inactive infusion - this is a solution that looks like the study drug but has no active ingredient).

• Group 2: Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 10, 14 and 22.

This multi-center trial will be conducted worldwide. The overall time to participate in this study from screening to 18 weeks after the last dose is 44 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: November 14, 2018
• Est. primary completion date: September 4, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

2. The participant or, when applicable, the participant's legally acceptable representative has signed and dated a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

3. Has a diagnosis of CD established at least 3 months prior to randomization by clinical and endoscopic evidence and corroborated by a histopathology report.

4. Has a diagnosis of a minimum of 1 perianal draining fistula of at least 2 weeks duration as a complication of moderately to severely active CD, as identified on magnetic resonance image (MRI) at Screening. Other types of fistulae (enterocutaneous, abdominal) except rectovaginal fistulae are permitted, but the number of perianal draining fistulae is limited to 3.

5. All countries except France: The participant, historically, had an inadequate response with, lost response to, or was intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-a) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula).

France only: The participant, historically, failed (ie, had an inadequate response with, lost response to, or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD.

6. If the participant had noncutting perianal seton placement as part of standard care, seton must be removed by Week 14 of the study.

Exclusion Criteria:

1. Has a diagnosis of ulcerative colitis or indeterminate colitis.

2. Has a perianal abscess greater than (>) 2 centimeter (cm) or an abscess that the investigator feels requires drainage based on either clinical assessment or MRI.

3. Has a Crohn's Disease Activity Index (CDAI) score >400.

4. Has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.

5. Has significant anal or rectal stenosis.

6. Has active or latent tuberculosis (TB), regardless of treatment history.

7. Has evidence of active Clostridium difficile (C. difficile) infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.

8. Has current rectovaginal fistula.

9. Currently has more than 3 draining perianal fistulae. Note: Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Drug:
• Vedolizumab
Vedolizumab 300 mg IV infusion
• Placebo
0.9% sodium chloride IV infusion

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	GIRI (GI Research Institute)	Vancouver	British Columbia
France	CHRU de Lille - Hopital Claude Huriez	Lille cedex
France	Hopital l'Archet II	Nice Cedex 3
France	CHU de Rennes - Hopital de Pontchaillou	Rennes cedex 9
France	Hopital de Brabois	Vandoeuvre les Nancy
Italy	Azienda Ospedaliera S. Orsola-Malpighi	Bologna
Italy	Istituto Clinico Humanitas IRCCS	Milan
Netherlands	Academic Medical Center	Amsterdam
Netherlands	Leids Universitair Medisch Centrum	Leiden
Netherlands	Erasmus MC	Rotterdam
Spain	Hospital Clinic Barcelona	Barcelona
Spain	Hospital Universitario y Politecnico La Fe	Valencia
United Kingdom	Nottingham University Hospitals NHS Trust	Nottingham
United Kingdom	John Radcliffe Hospital	Oxford
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Virginia Mason Medical Center	Seattle	Washington
United States	Texas Digestive Disease Consultants	Southlake	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Canada,  France,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)	Closed fistulae are no longer draining despite gentle finger compression.	Baseline, Week 30
Secondary	Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30	Closed fistulae are no longer draining despite gentle finger compression.	Weeks 22 and 30
Secondary	Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)	Closed fistulae are no longer draining despite gentle finger compression.	Week 30
Secondary	Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)	Closed fistulae are no longer draining despite gentle finger compression.The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.	Up to Week 30
Secondary	Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)	Closed fistulae are no longer draining despite gentle finger compression. The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.	Up to Week 30
Secondary	Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)	Duration of fistula response was measured by number of days with/without drainage. Duration of perianal fistula response (days) was derived as the sum of days with perianal fistula response between Day 1 and the end of the study (Week 30 or early discontinuation). Perianal fistula response is defined as reduction in the number of draining perianal fistulae (of those draining at Baseline) draining of at least 50%.	Up to Week 30